These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 36989355)

  • 21. ID2 expression in neuroblastoma does not correlate to MYCN levels and lacks prognostic value.
    Vandesompele J; Edsjö A; De Preter K; Axelson H; Speleman F; Påhlman S
    Oncogene; 2003 Jan; 22(3):456-60. PubMed ID: 12545167
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human neuroblastoma cells with MYCN amplification are selectively resistant to oxidative stress by transcriptionally up-regulating glutamate cysteine ligase.
    Veas-Perez de Tudela M; Delgado-Esteban M; Cuende J; Bolaños JP; Almeida A
    J Neurochem; 2010 May; 113(4):819-25. PubMed ID: 20180881
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Deregulated Wnt/beta-catenin program in high-risk neuroblastomas without MYCN amplification.
    Liu X; Mazanek P; Dam V; Wang Q; Zhao H; Guo R; Jagannathan J; Cnaan A; Maris JM; Hogarty MD
    Oncogene; 2008 Feb; 27(10):1478-88. PubMed ID: 17724465
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models.
    Wyce A; Ganji G; Smitheman KN; Chung CW; Korenchuk S; Bai Y; Barbash O; Le B; Craggs PD; McCabe MT; Kennedy-Wilson KM; Sanchez LV; Gosmini RL; Parr N; McHugh CF; Dhanak D; Prinjha RK; Auger KR; Tummino PJ
    PLoS One; 2013; 8(8):e72967. PubMed ID: 24009722
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas.
    Huang R; Cheung NK; Vider J; Cheung IY; Gerald WL; Tickoo SK; Holland EC; Blasberg RG
    FASEB J; 2011 Dec; 25(12):4138-49. PubMed ID: 21856782
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification and pharmacological inactivation of the MYCN gene network as a therapeutic strategy for neuroblastic tumor cells.
    Chayka O; D'Acunto CW; Middleton O; Arab M; Sala A
    J Biol Chem; 2015 Jan; 290(4):2198-212. PubMed ID: 25477524
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Crosstalk between MYCN and MDM2-p53 signal pathways regulates tumor cell growth and apoptosis in neuroblastoma.
    He J; Gu L; Zhang H; Zhou M
    Cell Cycle; 2011 Sep; 10(17):2994-3002. PubMed ID: 21862876
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distinct roles of two SEC scaffold proteins, AFF1 and AFF4, in regulating RNA polymerase II transcription elongation.
    Che Z; Liu X; Dai Q; Fang K; Guo C; Yue J; Fang H; Xie P; Luo Z; Lin C
    J Mol Cell Biol; 2024 Jan; 15(8):. PubMed ID: 37528066
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A SP1/MIZ1/MYCN repression complex recruits HDAC1 at the TRKA and p75NTR promoters and affects neuroblastoma malignancy by inhibiting the cell response to NGF.
    Iraci N; Diolaiti D; Papa A; Porro A; Valli E; Gherardi S; Herold S; Eilers M; Bernardoni R; Della Valle G; Perini G
    Cancer Res; 2011 Jan; 71(2):404-12. PubMed ID: 21123453
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Global MYCN transcription factor binding analysis in neuroblastoma reveals association with distinct E-box motifs and regions of DNA hypermethylation.
    Murphy DM; Buckley PG; Bryan K; Das S; Alcock L; Foley NH; Prenter S; Bray I; Watters KM; Higgins D; Stallings RL
    PLoS One; 2009 Dec; 4(12):e8154. PubMed ID: 19997598
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2.
    Chen L; Alexe G; Dharia NV; Ross L; Iniguez AB; Conway AS; Wang EJ; Veschi V; Lam N; Qi J; Gustafson WC; Nasholm N; Vazquez F; Weir BA; Cowley GS; Ali LD; Pantel S; Jiang G; Harrington WF; Lee Y; Goodale A; Lubonja R; Krill-Burger JM; Meyers RM; Tsherniak A; Root DE; Bradner JE; Golub TR; Roberts CW; Hahn WC; Weiss WA; Thiele CJ; Stegmaier K
    J Clin Invest; 2018 Jan; 128(1):446-462. PubMed ID: 29202477
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The MYCN oncoprotein as a drug development target.
    Lu X; Pearson A; Lunec J
    Cancer Lett; 2003 Jul; 197(1-2):125-30. PubMed ID: 12880971
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MYCN and SNRPD3 cooperate to maintain a balance of alternative splicing events that drives neuroblastoma progression.
    Salib A; Jayatilleke N; Seneviratne JA; Mayoh C; De Preter K; Speleman F; Cheung BB; Carter DR; Marshall GM
    Oncogene; 2024 Jan; 43(5):363-377. PubMed ID: 38049564
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma.
    Zhang S; Wei JS; Li SQ; Badgett TC; Song YK; Agarwal S; Coarfa C; Tolman C; Hurd L; Liao H; He J; Wen X; Liu Z; Thiele CJ; Westermann F; Asgharzadeh S; Seeger RC; Maris JM; Guidry Auvil JM; Smith MA; Kolaczyk ED; Shohet J; Khan J
    Cancer Lett; 2016 Feb; 371(2):214-24. PubMed ID: 26683771
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry.
    Durbin AD; Zimmerman MW; Dharia NV; Abraham BJ; Iniguez AB; Weichert-Leahey N; He S; Krill-Burger JM; Root DE; Vazquez F; Tsherniak A; Hahn WC; Golub TR; Young RA; Look AT; Stegmaier K
    Nat Genet; 2018 Sep; 50(9):1240-1246. PubMed ID: 30127528
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells.
    Slack AD; Chen Z; Ludwig AD; Hicks J; Shohet JM
    Cancer Res; 2007 Mar; 67(6):2448-55. PubMed ID: 17363562
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification.
    Valentijn LJ; Koster J; Haneveld F; Aissa RA; van Sluis P; Broekmans ME; Molenaar JJ; van Nes J; Versteeg R
    Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19190-5. PubMed ID: 23091029
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High level MycN expression in non-MYCN amplified neuroblastoma is induced by the combination treatment nutlin-3 and doxorubicin and enhances chemosensitivity.
    Peirce SK; Findley HW
    Oncol Rep; 2009 Dec; 22(6):1443-9. PubMed ID: 19885598
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DNA Ligase 4 Contributes to Cell Proliferation against DNA-PK Inhibition in
    Ando K; Suenaga Y; Kamijo T
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240360
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Histone lysine demethylase 4 family proteins maintain the transcriptional program and adrenergic cellular state of MYCN-amplified neuroblastoma.
    Abu-Zaid A; Fang J; Jin H; Singh S; Pichavaram P; Wu Q; Tillman H; Janke L; Rosikiewicz W; Xu B; Van De Velde LA; Guo Y; Li Y; Shendy NAM; Delahunty IM; Rankovic Z; Chen T; Chen X; Freeman KW; Hatley ME; Durbin AD; Murray PJ; Murphy AJ; Thomas PG; Davidoff AM; Yang J
    Cell Rep Med; 2024 Mar; 5(3):101468. PubMed ID: 38508144
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.